• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 11/14/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

antibodies

  • 1:40 PM

    – Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology organizations NEW YORK, ATNM, (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Jeannine Larrieux, Ph.D. has been appointed Director of Analytical Development. Dr. Larrieux will be responsible for analytical assay development, conducting biologics license application (BLA)

    Read more
  • 4:12 PM

    VANCOUVER, Washington, Sept. 12, 2016 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has entered into definitive agreements with healthcare dedicated institutional investors for an offering of 13,333,334 shares of common stock, at a price per share of $0.75, and warrants to purchase 6,666,667 shares of common stock with gross proceeds of approximately $10.0 million in a registered direct offering.

    Read more
  • 1:48 PM

    VANCOUVER, Washington, July 26, 2016, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces the enrollment of the first patient under a recently modified protocol in the Company’s Phase 3 combination study with PRO 14O (humanized monoclonal antibody to CCR5). The modified protocol has been cleared by the U.S. Food and Drug Administration (FDA) and features a 50% reduction in enrollment to 150

    Read more
  • 2:24 PM

    EDEN, N.C., July 3, 2014 /PRNewswire/ — Duke Energy has completed the cleanup of a coal ash deposit and river sediment at a site approximately two miles down river from the Dan River Steam Station. The location is where Town Creek meets the Dan River. The coal ash and sediment had accumulated on a sand bar. Crews excavated 258 tons of the material from the site over the last week. The removed material was taken to a landfill in Person County, N.C., where coal ash

    Read more
Public Wire Banner